|
个人信息Personal Information
教授 博士生导师 硕士生导师
性别：男
毕业院校：山东大学
学历：研究生(博士)毕业
学位：医学博士学位
在职信息：在职
所在单位：药学院
入职时间：2013-02-28
联系方式：zhangyingjie@sdu.edu.cn
扫描关注
- [81] 徐文方 , 张颖杰 and 高帅. Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups. Bioorganic & medicinal chemistry, 25, 2981, 2017.
- [82] 徐文方 , 张颖杰 and 臧杰. Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. Journal of Medicinal Chemistry, 61, 5304, 2018.
- [83] 徐文方 , 张颖杰 and 赵春龙. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 150, 282, 2018.
- [84] 徐文方 , 张颖杰 and 周楠. Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability. Bioorganic & medicinal chemistry, 25, 4614, 2017.
- [85] 徐文方 , 张颖杰 and 臧杰. Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity. Bioorganic & medicinal chemistry, 25, 2666, 2017.
- [86] 徐文方 , 张颖杰 and 高倩文. JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases. Current Drug Targets, 19, 487, 2018.
- [87] 杨新颖 , 徐文方 , 张颖杰 and 闫玉刚. Sulfoxide Analogs of TAK-875 as G Protein Coupled Receptor 40 Agonists: Synthesis, Determination of Absolute Configuration and Biological Activity. Chinese journal of organic chemistry, 37, 858, 2017.
- [88] 徐文方 , 张颖杰 and 高帅. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy. Anti-cancer agents in medicinal chemistry, 17, 802, 2017.
- [89] 徐文方 , 张颖杰 and 陈奉泉. Progress of CDK4/6 inhibitor palbociclib in the treatment of cancer. Anti-cancer agents in medicinal chemistry, 2018.
- [90] 杨新颖 , 徐文方 , 张颖杰 and 闫玉刚. G蛋白偶联受体40激动剂TAK-875亚砜类似物的合成、绝对构型确证及生物活性研究. 《有机化学》, 37, 858, 2017.
- [91] 张颖杰 , 徐文方 and 刘新泳. Discovery of N-Substituted Oseltamivir Derivatives as Potent and Selective Inhibitors of H5N1 Influenza Neuraminidase. J. Med. Chem, 2014.
- [92] 张颖杰 and 徐文方. Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity. Chem. Biol. Drug Des, 2013.
- [93] 张颖杰 and 徐文方. Discovery of a pair of diastereomers as potent HDACs inhibitors: determination of absolute configuration, biological activity comparison and computational study. Rsc Adv., 2013.
- [94] 张颖杰 and 徐文方. Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with an Indole-Containing Cap Group. ACS Med. Chem. Lett., 2013.
- [95] 张颖杰 , 徐文方 and 尹浩. 卡非佐米合成路线图解. 《中国药物化学杂志》, 27, 415, 2017.
- [96] 徐文方 , 张颖杰 , 吴敬德 and 李晓杨. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 134, 185, 2017.
- [97] 徐文方 and 张颖杰. Nitric oxide donor hybrid compounds as promising anticancer agents. Drug Discov. Ther., 2016.
- [98] 张颖杰. Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity. Bioorg. Med. Chem., 2016.
- [99] 徐文方 and 张颖杰. Design, Synthesis, and Antitumor Evaluation of 4？Amino-2 (1H)？pyrazole Derivatives as JAKs Inhibitors. ACS Med. Chem. Lett., 2016.
- [100] 徐文方 and 张颖杰. PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors. Chem. Biol. Drug Des., 2016.